Baxter Healthcare

DOXIL

  1. Home
  2.  / 
  3. Q Code
  4.  / DOXIL – Q2050

Manufacturer:

Baxter Healthcare

Name:

DOXIL

HCPCS Code Descriptor:

Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg

Category:

Q Code

HCPCS:

Q2050

NDC(s):

72603-0200-01, 72603-0103-01, 70710-1531-01, 70710-1530-01, 68001-0492-36, 68001-0493-26, 68001-0345-26, 68001-0345-36, 59676-0966-01, 59676-0966-02, 47335-0049-40, 47335-0050-40, 43598-0683-25, 43598-0682-35, 43598-0541-25, 43598-0283-35, 16714-0856-01, 16714-0742-01, 00574-0930-10, 00574-0931-25, 00338-0080-01, 00338-0086-01, 00338-0067-01, 00338-0063-01

Primary Type:

Oncology

Generic Status:

Multi-Source

Route of Administration:

Intravenous

About:

DOXIL is an Oncology drug manufactured by Baxter Healthcare and administered via the Intravenous route of administration. The Q Code: Q2050 is aligned to the drug DOXIL.

Access Pricing and More By Registering

HCPCS Added Date:

7/1/13

HCPCS Effective Date:

7/1/13

HCPCS Short Description:

Doxorubicin inj 10mg

Billing and Coding Guide:

Not Found

Patient Assistance:

Not Found